COMPOSITIONS AND METHODS FOR CORRECTING FOR CELLULAR ADMIXTURE IN EPIGENETIC ANALYSES
This disclosure relates to differentially methylated regions (DMRs) and an equation that can be applied when using epigenetic analysis in a biological sample that includes more than one cell type and, therefore, more than one methylation set point (e.g., saliva). This disclosure relates to differentially methylated regions (DMRs) and an equation that can be applied when using epigenetic analysis in a biological sample that includes more than one cell type and, therefore, more than one methylation set point (e.g., saliva).
1 . A method of correcting for cellular heterogeneity in an oropharyngeal biological sample used to determine the methylation status of a target nucleic acid sequence, the method comprising:
providing the oropharyngeal biological sample, the oropharyngeal biological sample comprising buccal cells and white blood cells;
determining the methylation status of the target sequence and at least one differentially methylated region (DMR) loci in the biological sample;
applying a formula to the methylation status of the target sequence and the at least one DMR loci in the biological sample to determine an amount of white blood cells and an amount of buccal cells in the biological sample; and
correcting for cellular heterogeneity in the biological sample when determining the DNA methylation status of the target sequence.
2 . The method of claim 1 , wherein the oropharyngeal biological sample is saliva or sputum.
3 . The method of claim 1 , wherein the absolute difference between the methylation status at the DMR loci in whole blood and at the DMR loci in buccal cells is at least 0.5.
4 . The method of claim 3 , wherein the absolute difference between the methylation status at the DMR loci in whole blood and the DMR loci in buccal cells is at least 0.8.
5 . The method of claim 3 , wherein the absolute difference between the methylation status at the DMR loci in whole blood and the DMR loci in buccal cells is at least 0.9.
6 . The method of claim 1 , wherein the DMR loci is selected from DMR11 (cg25574765), DMR20 (cg03841065), DMR11 (cg10511890), DMR12 (cg08075204), DMR7 (cg24620436), DMR20 (cg07598052), DMR16 (cg04921315), DMR11 (cg26427109), DMR2 (cg00438740), DMR6 (cg09344348), DMR11 (cg08141395), DMR10 (cg24681845), DMR19 (cg22824635), DMR4 (cg14516100), and DMR1 (cg20820767).
7 . The method of claim 1 , wherein the DMR loci is DMR16 and the formula comprises
DMR16(obs)=(0.97 X+ 0.18(1 −X ))
wherein DMR16(cg05575921)(obs) is the observed methylation signal in the heterogeneous biological sample; and X is the white blood cell contribution to the biological sample.
8 . The method of claim 1 , wherein the DMR loci is DMR11(cg08141395) and the formula comprises
DMR11(obs)=(0.01 X+ 0.99(1 −X ))
wherein DMR11(obs) is the observed methylation signal in the heterogeneous biological sample; and X is the white blood cell contribution to the biological sample.
9 . The method of claim 1 , wherein the determining step comprises PCR and/or sequencing.
10 . A method of correcting for cellular heterogeneity in a biological sample, comprising:
(a) providing a heterogeneous biological sample comprising buccal cells and white blood cells;
(b) contacting nucleic acid from the biological sample with bisulfite under alkaline conditions;
(c) performing methylation-sensitive PCR on the bisulfite-converted nucleic acid with a pair of primers that amplifies a first locus comprising at least one target CpG dinucleotide and a pair of primers that amplifies at least one DMR loci;
(d) determining the methylation status of the at least one target CpG dinucleotide and the methylation status of the at least one DMR loci; and
(e) correcting for cellular heterogeneity in the biological sample using a pre-determined formula.
11 . The method of claim 10 , wherein the absolute difference between the methylation status at the DMR loci in whole blood and the DMR loci in buccal cells is at least 0.5.
12 . The method of claim 11 , wherein the absolute difference between the methylation status at the DMR loci in whole blood and the DMR loci in buccal cells is at least 0.8.
13 . The method of claim 11 , wherein the absolute difference between the methylation status at the DMR loci in whole blood and the DMR loci in buccal cells is at least 0.9.
14 . The method of claim 10 , wherein the DMR is selected from DMR11 (cg25574765), DMR20 (cg03841065), DMR11 (cg10511890), DMR12 (cg08075204), DMR7 (cg24620436), DMR20 (cg07598052), DMR16 (cg04921315), DMR11 (cg26427109), DMR2 (cg00438740), DMR6 (cg09344348), DMR11 (cg08141395), DMR10 (cg24681845), DMR19 (cg22824635), DMR4 (cg14516100), and DMR1 (cg20820767).
15 . The method of claim 10 , wherein the DMR loci is DMR16 and the predetermined formula comprises
DMR16(obs)=(0.97 X+ 0.18(1 −X ))
wherein DMR16(obs) is the observed methylation signal in the biological sample; and X is the white blood cell contribution to the biological sample.
16 . The method of claim 10 , wherein the DMR loci is DMR11 and the predetermined formula comprises
DMR11(obs)=(0.01 X+ 0.99(1 −X ))
wherein DMR11(obs) is the observed methylation signal in the biological sample; and X is the white blood cell contribution to the biological sample.
17 . The method of claim 10 , wherein the determining step further comprises sequencing.
18 . A method for identifying a differentially methylated region (DMR) loci that can be used to correct for cellular heterogeneity in a biological sample, comprising:
(a) comparing the methylation status of a plurality of loci in a first component of the heterogeneous biological sample and the methylation status of a plurality of loci in a second component of the heterogeneous biological sample;
(b) identifying one or more loci from the plurality of loci that are differentially methylated in the first component of the heterogeneous biological sample relative to the second component of the heterogeneous biological sample, wherein the absolute difference between the methylation status in the first component and the methylation status in the second component of the one or more identified loci is at least 0.5,
thereby identifying a DMR loci that can be used to correct for cellular heterogeneity in a biological sample.
19 . The method of claim 18 , the absolute difference between the methylation status in the first component and the methylation status in the second component is at least 0.8.
20 . The method of claim 18 , the absolute difference between the methylation status in the first component and the methylation status in the second component is at least 0.9.
21 . The method of claim 18 , wherein the DMR is selected from DMR11 (cg25574765), DMR20 (cg03841065), DMR11 (cg10511890), DMR12 (cg08075204), DMR7 (cg24620436), DMR20 (cg07598052), DMR16 (cg04921315), DMR11 (cg26427109), DMR2 (cg00438740), DMR6 (cg09344348), DMR11 (cg08141395), DMR10 (cg24681845), DMR19 (cg22824635), DMR4 (cg14516100), and DMR1 (cg20820767).
22 . An article of manufacture to correct for cellular heterogeneity in a biological sample when determining the nucleic acid methylation status of a target sequence in the biological sample, comprising:
a first pair of DMR primers; and
at least one DMR probe that detects either a methylated or an unmethylated CpG dinucleotide.
23 . The article of manufacture of claim 22 , further comprising a second pair of DMR primers.
24 . The article of manufacture of claim 22 , comprising:
a first pair of DMR11 primers; and
at least one DMR11 probe that detects either a methylated or an unmethylated CpG dinucleotide.
25 . The article of manufacture of claim 24 , wherein the first pair of DMR11 primers comprises a first member and a second member, wherein the first member has the sequence shown in SEQ ID NO:12 and the second member has the sequence shown in SEQ ID NO:15.
26 . The article of manufacture of claim 24 , wherein the at least one DMR11 probe is selected from the sequence shown in SEQ ID NO:16 and the sequence shown in SEQ ID NO:17.
27 . The article of manufacture of claim 24 , further comprising a second pair of DMR11 primers.
28 . The article of manufacture of claim 27 , wherein the second pair of DMR11 primers comprises a first member and a second member, wherein the first member has the sequence shown in SEQ ID NO:13 and the second member has the sequence shown in SEQ ID NO:14.
29 . The article of manufacture of claim 22 , comprising:
a first pair of DMR16 primers; and
at least one DMR16 probe that detects either a methylated or an unmethylated CpG dinucleotide.
30 . The article of manufacture of claim 29 , wherein the first pair of DMR16 primers comprises a first member and a second member, wherein the first member has the sequence shown in SEQ ID NO:3 and the second member has the sequence shown in SEQ ID NO:5.
31 . The article of manufacture of claim 29 , wherein the at least one DMR16 probe is selected from the sequence shown in SEQ ID NO:7 and the sequence shown in SEQ ID NO:8.
32 . The article of manufacture of claim 29 , further comprising a second pair of DMR16 primers.
33 . The article of manufacture of claim 32 , wherein the second pair of DMR16 primers comprises a first member and a second member, wherein the first member has the sequence shown in SEQ ID NO:4 and the second member has the sequence shown in SEQ ID NO:6.
34 . The article of manufacture of claim 22 , wherein at least one member of the first pair of primers, at least one member of the second pair of primers, or the at least one probe comprises a modified nucleotide.
35 . The article of manufacture of claim 22 , further comprising reagents for bisulfite converting nucleic acid.
36 . The article of manufacture of claim 22 , further comprising reagents for amplifying nucleic acid.
37 . The article of manufacture of claim 22 , further comprising at least one probe that detects either the methylated or the unmethylated CpG dinucleotide.
38 . The article of manufacture of claim 22 , further comprising a minor groove binder (MGB).